Articles tagged with Blood Cancer
A new study published in Blood Advances reveals significant disparities in end-of-life care for individuals with hematologic malignancies living in rural areas versus metropolitan regions. Rural residents are less likely to receive hospice care, instead often dying in nursing facilities or at home without palliative care.
Researchers have discovered a new treatment that combines CAR-T cell therapy with interleukin-7 to enhance its effectiveness in treating blood cancers. The treatment results in significantly increased anti-tumor activity, improved survival rates, and reduced tumor growth in mice.
A new study found that adult survivors of childhood cancer are 80% more likely to be undertreated for cardiovascular risk factors, including hypertension, diabetes, and high cholesterol. The study highlights the need for increased awareness among healthcare professionals and improved health management strategies for cancer survivors.
A new study found that patients with multiple myeloma who received a three-drug combination therapy had improved progression-free survival if they underwent an autologous stem cell transplant soon after treatment. The use of maintenance lenalidomide also conferred substantial clinical benefit.
Researchers discovered that leukemia-initiating cells in MLL-rearranged B-ALL can switch between two metabolic states, which makes them difficult to target. Targeting the quiet, stem cell-like state curbs the leukemia by forcing the cells back to an active proliferation state.
Researchers found that hypomethylating agents can activate the SALL4 oncogene in patients with myelodysplastic syndrome, resulting in poor survival outcomes. Early intervention targeting SALL4 pathways may improve treatment and patient outcomes.
A new study published in Blood Advances found that virtual frailty assessments are both safe and feasible when conducted virtually. The study evaluated 185 patients with blood cancers who completed a virtual assessment, finding that 81.1% successfully completed the test without falls or safety events.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
Researchers have pinpointed a possible new target for treating patients with juvenile myelomonocytic leukemia (JMML), a highly aggressive blood cancer. Treatment using anti-inflammatories showed promise in rescuing JMML-like symptoms in zebrafish, suggesting a potential new approach to combating the disease.
A new sensor technology allows for real-time monitoring of lactate levels in the brain, providing insights into energy metabolism and potential applications in cancer detection. The sensors corrected for hemodynamic artifacts using MRI-informed corrections enable accurate cell-specific lactate level recordings.
A systematic review and meta-analysis of 81 studies found that COVID-19 patients with cancer had a higher risk of death compared to those without cancer. Younger age, lung, and hematologic cancers were identified as risk factors for poor outcomes from COVID-19
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
The study found significant heterogeneity among non-hematopoietic cells (NHCs) in human lymph nodes, with subgroups exhibiting distinct transcriptional changes and interaction patterns with malignant cells. This discovery may lead to the identification of potential biomarkers for therapeutic approaches.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
A UCLA-led team has created a roadmap tracing each step in human blood stem cell development, providing a blueprint for producing fully functional blood stem cells. The map could help expand treatment options for blood cancers and inherited disorders.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
A study by University of Helsinki researchers found that the immune system attacks itself in rare type of blood cancer. The immune system plays a role in the development and growth of cancer cells, making current therapies less effective.
A third dose of COVID-19 vaccine significantly increases immune responses in patients with multiple myeloma, but a subset remains vulnerable. The study found that 88% of patients developed antibodies after the third dose, leading to improved neutralization of the wild-type virus.
A study using the nation's largest COVID-19 data resource found that the vaccine protects most cancer patients from getting COVID, but those with certain types of cancer have a higher risk of breakthrough infections. The research also highlights the importance of continued vaccination efforts to protect cancer patients.
Researchers discovered that a genetic mutation causing odd-shaped nuclei may lead to earlier diagnosis and treatment of certain leukemias. The study found that the loss of nuclear Lamin B1 induces defects in nuclear morphology and genome instability, setting the stage for cancer.
The American Association for Cancer Research (AACR) has announced the recipients of its 2022 Scientific Achievement Awards and Lectureships, recognizing Tony Hunter, Christina Curtis, John E. Dick, Kevan M. Shokat, and Lee M. Ellis for their groundbreaking contributions to cancer research.
Hokkaido University scientists have identified CDK6 as a promising target for treating adult T-cell leukemia/lymphoma (ATLL) with the drug palbociclib. The combination of palbociclib with everolimus also showed significant tumor growth reduction and minimal side effects in mice models.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A new study from Vanderbilt University Medical Center found that 10-second videos of white blood cell motion can predict blood cancer relapse in stem cell and bone marrow transplant patients. The study showed that patients with high adherence levels and rolling along vessel walls were more than three times as likely to have a relapse o...
Dr. John E. Dick will receive the inaugural AACR Award for Outstanding Achievement in Blood Cancer Research for his groundbreaking discoveries on leukemic stem cells and their mechanisms. His research has provided crucial insights into leukemia progression, survival rates, and treatment response.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
The ZUMA-12 trial shows axi-cel achieved a high rate of complete response in patients with high-risk large B-cell lymphoma, with an estimated overall survival rate of 91% at 12 months.
Researchers at Cincinnati Children's Hospital Medical Center have identified a protein crucial to AML cell survival and found a small molecule that blocks its function, killing cancer cells in lab dishes and mouse models. This potential breakthrough could lead to novel therapies for AML and other conditions.
A new study has found that World Trade Center responders have an increased mutational burden, elevating their risk for blood cancers and cardiovascular disease. The researchers compared DNA samples from 203 Nashville firefighters to a control group of 52 firefighters who were not exposed to particulate matter at the disaster.
A study published in Nature Medicine defines distinct subgroups of stem cells that expand during MDS treatment and drive resistance. Researchers found that targeting these specific stem cell classes with therapies like venetoclax may improve outcomes for patients with disease progression.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a new therapeutic approach using a small-molecule inhibitor of the chromatin-modulatory enzyme EZH2 to target aggressive cancer cells. The treatment also targets cMyc, a prominent cancer-causing factor, and shows profound tumor killing effects.
Researchers have identified a group of clinical signs that can be paired with genetic testing to better inform the timing of more aggressive treatment for leukemia patients. The study used a mouse model to understand how genetic mutations trigger bone marrow failure and life-threatening complications.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
A recent study found that gene therapy delivery vectors were unlikely to cause the blood malignancies reported in trials; however, the exact cause remains a mystery. The study's results suggest that cancer risk in sickle cell disease may be more complex than initially thought, warranting further investigation.
Paczesny will explore biomarkers and a new type of immune cell to identify and regulate acute lung injury after BMT. She aims to improve understanding of signaling mechanisms in lung injury after BMT, particularly as they relate to idiopathic pneumonia syndrome.
A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Scientists from Japan and USA develop a microfluidic device for purification of tuberculosis genomic DNA fragments, enabling accurate diagnosis of diseases. The device uses transient ITP and electrokinetic trapping to detect and purify small cfDNA fragments.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Researchers have developed a personalized dosing regime for anti-thymocyte globulin (ATG) to improve the success of stem cell transplants in children with leukemia. The new approach led to better immune recovery and higher survival rates compared to standard treatment.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
Researchers confirm contagious blood cancer can jump between marine clam species, with evidence suggesting human activities may contribute to the spread. The discovery highlights the potential ecological threat posed by these diseases and emphasizes the need for further studies to monitor pathogens.
Researchers at Cold Spring Harbor Laboratory discovered a previously unknown protein called SCP4 that plays a crucial role in the survival of acute myeloid leukemia cells. The study found that SCP4 can pair with specific kinases to regulate cell activity, and targeting this pathway may lead to effective treatment options.
A new graft strategy has reduced chronic graft-versus-host disease in leukemia patients by depleting naïve T cells from donor blood. The approach has shown promising results, with only 7% of patients developing chronic GVHD compared to 30-60% with standard treatment.
Scientists develop hairy cellulose nanocrystals to capture and remove excess chemotherapy drugs from the blood. The nanocrystals effectively removed over 6,000 milligrams of doxorubicin per gram, increasing DOX capture by two to three orders of magnitude compared to existing methods.
A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
Scientists at La Jolla Institute for Immunology have discovered a link between TET enzyme deficiency and the formation of unusual DNA structures, such as G-quadruplexes and R-loops, which contribute to genomic instability. The study suggests that regulating these structures may be key to controlling cancer development.
A new study published in Nature found that valine is essential for the growth of T cell acute lymphoblastic leukemia, a type of childhood blood cancer. Blocking valine-linked genes led to decreased valine levels and stalled tumor cells from growing.
A new blood test developed at Hebrew University of Jerusalem detects immune and inflammatory activity in tissues by monitoring circulating DNA fragments. This method provides accurate information about immune processes in remote tissues, removing the need for invasive measures.
A novel approach may reduce the serious adverse effect of cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Supressing interferon gamma (IFNγ) appears to prevent activation of macrophages and other immune cells that drive the syndrome without impacting CAR T-cell efficacy.
Researchers mapped how HTLV-1 transforms T-cells into cancerous cells, revealing the virus over-activates them and makes them more vulnerable to DNA damage. This study provides new directions for potential treatments to prevent cancer development.
Researchers identified specific metabolic vulnerabilities in leukemia cell lines, including sensitivity to PI3K and fatty acid synthase inhibitors. The study highlights the potential for targeted cancer therapy by exploiting these dependencies.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.